One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
What is the value of faster acting prandial insulin? Focus on ultra rapid lispro
Tim Heise MD, Carolina Piras de Oliveira MD, Rattan Juneja MD, Anderson Ribeiro MD, Farai Chigutsa MPH, Thomas Blevins MD,Â
doi : 10.1111/dom.14773
Rapid-acting insulins (RAIs) have been instrumental in the management of diabetes because of their improved postprandial glucose (PPG) control compared with regular human insulin. However, their absorption rate and time action following subcutaneous administration still falls short of the normal physiological response to meal consumption, increasing the risk of early postmeal hyperglycaemia and late postmeal hypoglycaemia.
Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications
Ilias D. Vachliotis MD, Athanasios D. Anastasilakis MD, Antonis Goulas MD, Dimitrios G. Goulis MD, Stergios A. Polyzos MD,Â
doi : 10.1111/dom.14774
Nonalcoholic fatty liver disease (NAFLD) and osteoporosis are two highly prevalent metabolic diseases. Increasing experimental evidence supports a pathophysiological link between NAFLD and osteoporosis.
Polarized macrophages promote gestational beta cell growth through extracellular signal-regulated kinase 5 signalling
Yinan Jiang PhD, Apeng Chen PhD, Diana Kline BA, Qun Liu MD, Jie Ma MPH, Yan Wang PhD, Ting Zhang PhD, Jieqi Qian MD, Laura Nelson BA, MD, Krishna Prasadan PhD, Baoli Hu PhD, George K. Gittes MD, Xiangwei Xiao MD, PhD,Â
doi : 10.1111/dom.14744
To show that depletion of pancreatic macrophages impairs gestational beta cell proliferation and leads to glucose intolerance.
Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global DISCOVER study
Vittal Hejjaji MD, Juan J. Gorgojo-Martinez MD, Fengming Tang MS, Julia Blanco Garnelo MS, Andrew Cooper MSc, Jesús Medina PhD, Miren Sequera Mutiozabal PhD, Kamlesh Khunti MD, Antonio Nicolucci MD, Marina V. Shestakova MD, Linong Ji MD, Marilia B. Gomes MD, Hirotaka Watada MD, Jiten Vora MD, Ali O. Malik MD, Mikhail Kosiborod MD, Suzanne V. Arnold MD,Â
doi : 10.1111/dom.14745
To estimate real-world change in weight over 3 years and the factors influencing it in participants who are overweight and live with type 2 diabetes.
Liraglutide increases islet Ca2+ oscillation frequency and insulin secretion by activating hyperpolarization-activated cyclic nucleotide-gated channels
Karolina E. Zaborska, Kelli L. Jordan, Ariel S. Thorson, Prasanna K. Dadi, Charles M. Schaub, Arya Y. Nakhe, Matthew T. Dickerson, Joshua C. Lynch, Adam J. Weiss, Jordyn R. Dobson, David A. Jacobson,Â
doi : 10.1111/dom.14747
To determine whether hyperpolarization-activated cyclic nucleotide-gated (HCN) channels impact glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) modulation of islet Ca2+ handling and insulin secretion.
Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial
Edward Franek MD, Hertzel C. Gerstein MD, MSc, Matthew C. Riddle MD, Claudia Nicolay PhD, Ana Hickey PhD, Fady T. Botros PhD, Li Shen Loo PhD,Â
doi : 10.1111/dom.14760
To assess cardiovascular, glycaemic, weight and safety outcomes of long-term treatment with dulaglutide 1.5 mg compared with placebo in patients with a baseline HbA1c of less than 7% versus 7% or higher.
Reduced hypoglycaemia using liver-targeted insulin in individuals with type 1 diabetes
Ruth S. Weinstock MD, Bruce W. Bode MD, Satish K. Garg MD, David C. Klonoff MD, Caroline El Sanadi PhD, W. Blair Geho MD, Douglas B. Muchmore MD, Marc S. Penn MD,Â
doi : 10.1111/dom.14761
To investigate whether an increased bolus: basal insulin ratio (BBR) with liver-targeted bolus insulin (BoI) would increase BoI use and decrease hypoglycaemic events (HEv).
Effect of expanded dulaglutide weekly doses (3.0Â mg and 4.5Â mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study
David A. Cox PhD, Hui Wang PhD, Claudia Nicolay PhD, Mary Angelyn Bethel MD,Â
doi : 10.1111/dom.14762
This post hoc analysis investigated the effect of dulaglutide on cardiovascular disease (CVD) risk factors in subgroups of participants at increased CVD risk in the AWARD-11 study.
Interindividual variability in average glucose-glycated haemoglobin relationship in type 1 diabetes and implications for clinical practice
Yongjin Xu PhD, Richard M. Bergenstal MD, Timothy C. Dunn PhD, Yashesvini Ram PhD, Ramzi A. Ajjan MD, PhD,Â
doi : 10.1111/dom.14763
Glycated haemoglobin (HbA1c) can fail to reflect average glucose levels, potentially compromising management decisions. We analysed variability in the relationship between mean glucose and HbA1c in individuals with diabetes.
Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial
Monika Kellerer MD, Margit Staum Kaltoft MD, Jack Lawson MBBS, Lasse Lykke Nielsen MSc, Krzysztof Strojek MD, Ömür Tabak MD, Stephan Jacob MD,Â
doi : 10.1111/dom.14765
To compare the efficacy and safety of once-weekly (OW) semaglutide versus thrice-daily (TID) insulin aspart (IAsp) in participants with inadequately controlled type 2 diabetes (T2D) treated with insulin glargine (IGlar) and metformin.
A double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5Â mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study
Soree Ryang, Sang Soo Kim, Ji Cheol Bae, Ji Min Han, Su Kyoung Kwon, Young Il Kim, Il Seong Nam-Goong, Eun Sook Kim, Mi-kyung Kim, Chang Won Lee, Soyeon Yoo, Gwanpyo Koh, Min Jeong Kwon, Jeong Hyun Park, In Joo Kim,Â
doi : 10.1111/dom.14766
To compare the efficacy and safety of adding low-dose lobeglitazone (0.25 mg/day) or standard-dose lobeglitazone (0.5Â mg/day) to patients with type 2 diabetes mellitus (T2DM) with inadequate glucose control on metformin and dipeptidyl peptidase (DPP4) inhibitor therapy.
Type 2 diabetes subgroups and response to glucose-lowering therapy: Results from the EDICT and Qatar studies
Tamam Abdul-Ghani MSc, Curtiss Puckett NP, Osama Migahid MD, Siham Abdelgani MD, Ayman Migahed MD, John Adams MSc, Curtis Triplitt Pharm D, Ralph DeFronzo MD, Amin Jayyousi MD, Muhammad Abdul-Ghani MD,Â
doi : 10.1111/dom.14767
To examine the efficacy of glucose-lowering medications in subgroups of patients with type 2 diabetes mellitus (T2DM).
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US-licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE-3 (Recombinant Human INsulin Equivalence-3) study
Leona Plum-Mörschel MD, PhD, Oliver Klein MD, Gursharan Singh MBBS, PhD, Sundara Moorthi Nainar Murugesan MPharm, PhD, Ashwani Marwah MSc, Nirant Sharma MSc, Jayanti Panda MPharm, Subramanian Loganathan MD, Gopu Chandrasekharan Lakshmi MPharm, PhD, Sandeep N. Athalye MS,Â
doi : 10.1111/dom.14768
To establish the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of proposed biosimilar insulin 70/30 (Biocon's Insulin-70/30) and HUMULIN® 70/30 (HUMULIN-70/30; Eli Lilly and Company, IN).
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus
Matthew W. Segar MD, Ahmed A. Kolkailah MD, Robert Frederich MD, Annpey Pong PhD, Christopher P. Cannon MD, Francesco Cosentino MD, Samuel Dagogo-Jack MD, Darren K. McGuire MD, Richard E. Pratley MD, Chih-Chin Liu PhD, Mario Maldonado MD, Jie Liu MD, Nilo B. Cater MD, Ambarish Pandey MD, David Z. I. Cherney MD,Â
doi : 10.1111/dom.14769
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce the risk of hospitalization for heart failure (HHF) and composite kidney outcomes, but the mediators underlying these benefits are unknown.
Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial
Lorenzo Piemonti MD, Bart Keymeulen MD, Pieter Gillard MD, Thomas Linn MD, Emanuele Bosi MD, Ludger Rose MD, Paolo Pozzilli MD, Francesco Giorgino MD, Efisio Cossu MD, Luisa Daffonchio PhD, Giovanni Goisis PhD, Pier Adelchi Ruffini MD, Anna Rita Maurizi MD, Flavio Mantelli MD, Marcello Allegretti PhD,Â
doi : 10.1111/dom.14770
To evaluate the ability of ladarixin (LDX, 400 mg twice-daily for three cycles of 14 days on/14 days off), an inhibitor of the CXCR1/2 chemokine receptors, to maintain C-peptide production in adult patients with newly diagnosed type 1 diabetes.
The impact of the COVID-19 pandemic on glycaemic control in people with diabetes: A systematic review and meta-analysis
Lauren L. O'Mahoney PhD, Patrick J. Highton PhD, Laura Kudlek MSc, Jessica Morgan BA, Rosie Lynch BA, Ella Schofield BMBCh, Nayanika Sreejith BA, Ajay Kapur BMBCh, Afolarin Otunla BA, Sven Kerneis BMBCh, Olivia James BA, Karen Rees PhD, Ffion Curtis PhD, Kamlesh Khunti FMedSci, Jamie Hartmann-Boyce DPhil,Â
doi : 10.1111/dom.14771
To identify, appraise and synthesize the available evidence on the impact of the coronavirus disease 2019 (COVID-19) pandemic and lockdown (LD) on glycaemic control in people with diabetes.
Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison
Karan Vadher MSc, Hiren Patel MPharm, Reema Mody PhD, Joshua A. Levine MD, Meredith Hoog MPH, Alice YY. Cheng MD, Kevin M. Pantalone DO, Hélène Sapin MSc,Â
doi : 10.1111/dom.14775
To conduct an adjusted indirect treatment comparison (aITC) of the efficacy of tirzepatide 5/10/15 mg versus semaglutide 2 mg in patients with type 2 diabetes.
Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: A systematic review and meta-analysis
Daniel Yuan, Harman Sharma, Anirudh Krishnan, Venkat N. Vangaveti MSc, PhD, Usman H. Malabu FRCP,Â
doi : 10.1111/dom.14776
To determine the effect of glucagon-like peptide 1 receptor agonists (GLP-1RAs) on albuminuria in adult patients with type 2 diabetes mellitus (T2DM).
Acute concomitant glucose-dependent insulinotropic polypeptide receptor antagonism during glucagon-like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity
Signe Stensen MD, Liva L. Krogh MD, Alexander H. Sparre-Ulrich PhD, Flemming Dela MD, Bolette Hartmann PhD, Tina Vilsbøll MD, Jens J. Holst MD, Mette M. Rosenkilde MD, Mikkel B. Christensen MD, Lærke S. Gasbjerg MD, Filip K. Knop MD,Â
doi : 10.1111/dom.14736
A comment on metformin and COVID-19 with regard to “Metformin use is associated with a decrease in the risk of hospitalization and mortality in COVID-19 patients with diabetes: A population-based study in Lombardy�
Abdallah Al-Salameh, Nicolas Wiernsperger, Bertrand Cariou, Jean-Daniel Lalau,Â
doi : 10.1111/dom.14746
